Your session is about to expire
← Back to Search
non-invasive Meibomian gland (MG) expression for Meibomian Gland Dysfunction
Study Summary
This trial explores how MGD dry eye affects sight & how non-invasive MG expression can improve vision.
- Meibomian Gland Dysfunction
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this research still actively recruiting participants?
"This research is not presently recruiting participants. Originally posted to clinicaltrials.gov on February 6th, 2023 and updated lastly on the 1st of February in that same year, this trial is no longer accepting candidates at present; however there are 84 other studies actively searching for volunteers now."
What are the chief aims of this medical experiment?
"This research endeavour has the purpose of measuring a change in Response Time on Cone Contrast Test (CCT, Innova Systems, Inc.) over an allocated time period. Supplementary outcomes monitored include Change in Response Time on Black White Contrast Sensitivity Test (Innova Systems, Inc) which gauges reaction speed to low contrast black/white letters; Change in Visual Acuity Test at Low Contrast (Innova Systems, Inc), used for evaluating minimal visible low contrast characters; and Change in Response Time on Visual Acuity Test at Low Contrast (Innova Systems, Inc) which assesses average response time when identifying small scale visual acuity symbols"
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger